P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy
Title:
P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy
Author:
Bardia, A. Pusztai, L. Albain, K. Kalinsky, K. Hershman, D. Barlow, W. Tokunaga, E. Ciruelos, E.M. Loirat, D. Isaacs, C. Testa, L. Dry, H. Kozarski, R. Maxwell, M. Harbeck, N. Sharma, P.